Merck & Co (MRK) DIvidends Date & History

Key Takeaways

• MRK pays a quarterly dividend of $0.85 per share, totaling $3.40 annually.
• The current dividend yield stands at approximately 2.6%.
• The payout ratio remains in a sustainable range, supported by solid cash flows.
• MRK has a consistent history of dividend increases over multiple years.
• The dividend profile positions MRK as a moderate-yield dividend growth stock in the pharmaceutical sector.
• Upcoming ex-dividend date is September 15, 2026, with payment on October 7, 2026.

Dividend Overview

Merck & Co., Inc. (MRK) maintains a straightforward quarterly dividend policy. The company currently distributes $0.85 per share each quarter, equating to an annualized payout of $3.40. This results in a dividend yield of roughly 2.6%, based on recent share prices. MRK qualifies as a dividend growth stock with a modest yield profile rather than a high-yield name. Payments occur four times per year, providing predictable income for shareholders. The policy reflects a balanced approach that supports both shareholder returns and ongoing business investments in pharmaceutical research and development.

Dividend History and Growth

MRK has demonstrated steady dividend growth over time. The quarterly payout has risen from lower levels in prior years to the current $0.85 per share. Historical data shows multiple increases, with a five-year dividend growth rate near 5.75%. The company maintains a long record of consistent quarterly payments without cuts. This pattern aligns with a long-term strategy of gradual dividend expansion supported by earnings and cash generation from its core pharmaceutical operations.

Dividend Sustainability and Payout Ratio

The dividend appears sustainable given MRK’s financial position. Reported payout ratios range from approximately 44% to the low 90s percent depending on the measurement period and earnings volatility, yet remain supported by free cash flow. The company’s strong balance sheet, consistent profitability in key therapeutic areas, and disciplined capital allocation help ensure coverage. Debt levels are manageable, and earnings provide adequate coverage for the current payout. Overall financial stability supports continued dividend payments at the present level.

Dividend Compared to Industry Peers

Within the pharmaceutical sector, MRK’s dividend yield of about 2.6% sits near the middle of the peer range. It trails higher-yielding names such as Pfizer (PFE) at over 6% and Bristol-Myers Squibb (BMY) near 3.8%, while aligning closely with peers like Amgen (AMGN) and Novartis (NVS). The moderate yield combined with a history of increases offers a balanced profile compared with more aggressive or lower-yielding competitors in the same industry.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify dividend stocks, income-focused investments, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. AI Screener

Is This Stock Attractive for Dividend Investors?

MRK may appeal to dividend growth investors seeking moderate yields with a track record of increases and long-term payment consistency. Income-oriented investors could find the quarterly schedule and pharmaceutical sector stability suitable for portfolio diversification. Conservative, long-term holders may value the sustainability metrics and cash flow support. The profile is less suited for those prioritizing the highest current yields available in the broader market. Investors should evaluate the stock against their individual income needs, time horizon, and risk tolerance.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations